Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.43 |
| ▸ | CTSL | P07711 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256754 | 0.99 | CTSS (0.44) | CTSSCTSLKCNH2CTSKPRKCQ | |
| SCHEMBL5259187 | 0.78 | KMT2A (0.43) | GBA1JAK2JAK1 | |
| SCHEMBL5255861 | 0.77 | CDK1 (0.39) | CTSSCTSLCTSKLRRK2 | |
| SCHEMBL3450564 | 0.76 | CTSK (0.51) | CTSSCTSLCTSK | |
| SCHEMBL3453193 | 0.75 | CTSK (0.54) | CTSSCTSLCTSK | |
| SCHEMBL5256570 | 0.74 | CTSS (0.51) | CTSSCTSLKCNH2CTSK | |
| SCHEMBL3451474 | 0.73 | CTSS (0.50) | CTSSCTSLKCNH2CTSK | |
| SCHEMBL5258665 | 0.71 | CTSS (0.41) | CTSSCTSLKCNH2CTSKPRKCQ | |
| SCHEMBL4129300 | 0.71 | CTSK (0.46) | CTSSCTSLKCNH2CTSKLRRK2 | |
| SCHEMBL31480308 | 0.69 | CDK1 (0.36) | CTSSCTSLCTSKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100562319-C | 2-cyanopyrrole and pyrimidine and its pharmaceutical use | NOVARTIS AG (CH) | 2009-11-25 | — | — | CN | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| CN-1756553-A | 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | CTSS 2927/4885CTSL 3093/4885KCNH2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.